Pyridopyrimidinone compound and application thereof
By developing pyridopyrimidinone compounds that can effectively inhibit KRAS G12C mutation, we have solved the problem of limited therapeutic effect on cancers related to KRAS G12C mutation in the existing technology, and achieved effective treatment of diseases such as non-small cell lung cancer and colorectal cancer.
Patent Information
- Application Number
- CN202011182716.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-02-04
- Filing Date
- 2020-10-29
- Publication Date
- 2021-01-01
- Estimated Expiration
- 2040-10-29
AI Technical Summary
Existing treatments for cancers related to KRAS G12C mutations have limited effects and lack effective targeted drugs. Especially in diseases such as non-small cell lung cancer and colorectal cancer, traditional drugs are difficult to effectively inhibit the activity of KRAS protein.
A new class of pyridopyrimidinone compounds has been developed that can effectively inhibit KRAS G12C mutations and serve as potential therapeutic drugs for the treatment of malignant tumors carrying KRAS G12C mutations, especially non-small cell lung cancer and colorectal cancer.
The pyridopyrimidinone compound significantly inhibits KRAS G12C mutation, has strong anti-cell proliferation activity, and has great application value in preventing and treating malignant tumors carrying KRAS G12C mutation.
